500.05 Comparison Between Fractional Flow Reserve (FFR) vs. Computational Fractional Flow Reserve Derived from Three-dimensional Intravascular Ultrasound (IVUSFR) and Quantitative Flow Ratio (QFR)

BACKGROUND The determination of the ischemic status of a coronary artery by wireless physiologic assessment derived from angiography has been validated and approved in the US. However, the use ofplain angiography quantitative variables does not add much to thephysiology data since it has low correlation with fractional flowreserve (FFR) and predicts clinical outcomes poorly. Recently, a grayscale intravascular ultrasound (IVUS) derived physiology method(IVUSFR) was developed and showed a good correlation with invasiveFFR by combining the geometric advantages of IVUS with physiology.The aim of this study is to assess the coefficient of correlation (R) ofinvasive FFR compared to IVUSFR and quantitative flow ratio (QFR).METHODS Stable coronary artery disease (CAD) patients with intermediate lesions (i.e. 40?80% of diameter stenosis) were assessed by angiography and IVUS. QFR was derived from the angiography images, andIVUSFR was derived from quantitative IVUS data using computationalfluid dynamics. Coefficient of correlation (R) was used in this report.RESULTS Twenty-four patients with 34 lesions were included in theanalysis. The IVUSFR, invasive FFR, Vessel QFR fixed flow (vQFRf),and Vessel QFR contrast flow (vQFRc) values varied from 0.52 to 1.00,0.71 to 0.99, 0.55 to 1.00, and 0.34 to 1.00, respectively. The coefficient of correlation (R) of FFR vs. IVUSFR was 0.79; FFR vs. vQFRf was0.72; FFR vs. vQFRc was 0.65 (Figure).CONCLUSION Compared to invasive FFR, IVUSFR and vQFRf showed asimilar coefficient of correlation and were better than vQFR contrast flowFil: Kajita, Alexandre. Medstart; Estados UnidosFil: Bezerra, Cristiano Guedes. Universidade Federal da Bahia; BrasilFil: Ozaki, Yuichi. Medstart; Estados UnidosFil: Dan, Kazuhiro. Medstart; Estados UnidosFil: Melaku, Gebremedhin D.. Medstart; Estados UnidosFil: Pinton, Fabio A.. Universidade de Sao Paulo; BrasilFil: Falcão, Breno A. A.. Hospital of Messejana; BrasilFil: Mariani, José. Universidade de Sao Paulo; BrasilFil: Bulant, Carlos Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. National Laboratory For Scientific Computing; BrasilFil: Maso Talou, Gonzalo Daniel. National Laboratory For Scientific Computing; BrasilFil: Esteves, Antonio. Universidade de Sao Paulo; BrasilFil: Blanco, Pablo Javier. National Laboratory For Scientific Computing; BrasilFil: Waksman, Ron. Medstart; Estados UnidosFil: Garcia Garcia, Hector M.. Medstart; Estados UnidosFil: Lemons, Pedro Alves. Universidade de Sao Paulo; Brasi

Standards for quantitative assessments by coronary computed tomography angiography (CCTA)

In current clinical practice, qualitative or semi-quantitative measures are primarily used to report coronary artery disease on cardiac CT. With advancements in cardiac CT technology and automated post-processing tools, quantitative measures of coronary disease severity have become more broadly available. Quantitative coronary CT angiography has great potential value for clinical management of patients, but also for research. This document aims to provide definitions and standards for the performance and reporting of quantitative measures of coronary artery disease by cardiac CT.</p

Comparison of clinical outcomes between Magmaris and Orsiro drug eluting stent at 12 months: Pooled patient level analysis from BIOSOLVE II–III and BIOFLOW II trials

Background: The aim of this study was to compare the 12-month clinical outcomes of patients treated with Magmaris or Orsiro. Second generation drug-eluting absorbable metal scaffold Magmaris (Dreams 2G) has proved to be safe and effective in the BIOSOLVE-II study. Similarly, biodegradable polymer sirolimus-eluting stent, Orsiro has shown notable clinical results even in all-comer populations. Methods: Magmaris group patients were taken from the BIOSOLVE-II and BIOSOLVE-III trials, while the patients from Orsiro group were enrolled in BIOFLOW-II trial. The primary outcome was explored using a time-to-event assessment of the unadjusted clinical outcomes for target lesion failure (TLF) at 12 months, followed by a multivariate analysis adjusting for all the significantly different covariates between the groups. Results: The study population consisted of 482 patients (521 lesions), 184 patients (189 lesions) in Magmaris group and 298 patients (332 lesions) in Orsiro group. The mean age was 65.5 ± 10.8 and 62.7 ± 10.4 years in Magmaris and Orsiro groups, respectively (p = 0.005). Magmaris and Orsiro unadjusted TLF rates were 6.0 and 6.4% with no significant difference between the groups (p = 0.869). In the multivariate analysis, there were no meaningful differences between Magmaris and Orsiro groups. Finally, none of the groups presented device thrombosis cases at 12 months. Conclusion: At 12 months there were no significant differences between Magmaris and Orsiro groups neither in the unadjusted assessment nor in the multivariate analysis for target lesion failure. These results should be taken as hypothesis generating and may warrant a head to head comparison on a randomized fashion

Ultralight vector dark matter search using data from the KAGRA O3GK run

Among the various candidates for dark matter (DM), ultralight vector DM can be probed by laser interferometric gravitational wave detectors through the measurement of oscillating length changes in the arm cavities. In this context, KAGRA has a unique feature due to differing compositions of its mirrors, enhancing the signal of vector DM in the length change in the auxiliary channels. Here we present the result of a search for U(1)B−L gauge boson DM using the KAGRA data from auxiliary length channels during the first joint observation run together with GEO600. By applying our search pipeline, which takes into account the stochastic nature of ultralight DM, upper bounds on the coupling strength between the U(1)B−L gauge boson and ordinary matter are obtained for a range of DM masses. While our constraints are less stringent than those derived from previous experiments, this study demonstrates the applicability of our method to the lower-mass vector DM search, which is made difficult in this measurement by the short observation time compared to the auto-correlation time scale of DM

The Development of Magnesium-Based Resorbable and Iron-Based Biocorrodible Metal Scaffold Technology and Biomedical Applications in Coronary Artery Disease Patients

In the treatment of atherosclerotic disease patients, the adoption of second-generation drug-eluting stents (DES) in percutaneous coronary intervention reduced the occurrence of in-stent restenosis (ISR) and acute stent thrombosis (ST) when compared to bare metal stents and 1st generation DES. However, the permanent encaging of the vessel wall by any of the metallic stents perpetuates the inflammation process and prevents vasomotion in the treated segment. Aiming to overcome this issue, the bioresorbable scaffold (BRS) concept was developed by providing transient vascular radial support to the target segment during the necessary time to heal and disappearing after a period of time. Close to 20 years since BRS technology was first reported, the interventional cardiology field saw the rise and fall of several BRS devices. Although iron-based BRS is an emerging technology, currently, magnesium-alloy resorbable scaffolds devices are supported with the most robust data. This manuscript aims to review the concept of magnesium-based BRS devices, as well as their bioresorption mechanisms and the status of this technology, and the clinical outcomes of patients treated with magnesium BRS and to review the available evidence on iron-based BRS technology